Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2018 Mar 28;17(6):1196–1206. doi: 10.1158/1535-7163.MCT-17-0682

Figure 1. Anti-tumor efficacy of nano-engineered MSCs.

Figure 1

(A and B) Mice bearing orthotopic A549 lung tumors were intravenously injected with saline; untreated MSCs (MSC); MSCs engineered with blank nanoparticles (MSC + Blank NP); paclitaxel solution (PTX solution), PTX-loaded nanoparticles (PTX NP); or nano-engineered MSCs (MSC + PTX NP). (A) Plot of normalized bioluminescence readings (± SEM; n=7 for MSC + PTX NP and PTX NP group and n= 6 for all other groups). * significantly different (P < 0.05) from PTX solution; # significantly different (P < 0.05) from PTX NP. (B) Kaplan–Meier survival curves for the different treatment groups. Log-rank test of MSC + PTX NP and each control group yielded P < 0.0001 (*). (C and D) Mice bearing orthotopic Ll/2 lung tumors were intravenously injected with saline; untreated MSCs (MSC); untreated mouse MSCs (mMSC); MSCs engineered with blank nanoparticles (MSC + Blank NP); mouse MSCs engineered with blank nanoparticles (mMSC + Blank NP); paclitaxel solution (PTX solution), PTX-loaded nanoparticles (PTX NP); nano-engineered MSCs (MSC + PTX NP), or nano-engineered mouse MSCs (mMSC + PTX NP). Normalized bioluminescence readings (± SEM; n=7) for (C) human nano-engineered MSCs and (D) mouse nano-engineered MSCs. The insets in C and D show data for PTX solution, PTX NP, MSC + PTX NP, and mMSC + PTX NP on days 14, 18, and 20. For C and D, PTX solution, PTX NP, MSC + PTX NP, and mMSC + PTX NP are significantly different from non-drug controls (P < 0.05)